Methotrexate formulation and dosing errors in rheumatology practice: a perspective from Pakistan
Health Innovation Reports · 2026
DOI: 10.64048/hir.v2n2.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Innovation Reports, 2026. Verfasst von Nauman Ismat Butt. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Methotrexate is a cornerstone disease-modifying antirheumatic drug for rheumatoid arthritis, systemic lupus erythematosus and other inflammatory rheumatic diseases, yet its once-weekly regimen leaves it vulnerable to preventable and sometimes fatal dosing errors. In Pakistan and the wider South Asian region, this risk is compounded by multiple tablet strengths, look-alike packaging, inconspicuous once-weekly labelling, dispensing by non-pharmacist staff and the oral use of injectable preparations for cost reasons. Regulators in Europe and the United Kingdom have introduced packaging, labelling and prescribing safeguards, but comparable measures are not consistently applied in the region. This letter argues that better formulation design, standardised packaging with prominent weekly-dose alerts and pharmacist-led dispensing are essential to reduce methotrexate-related harm in rheumatology practice.
Zitieren
APA
Butt, N. I. (2026). Methotrexate formulation and dosing errors in rheumatology practice: a perspective from Pakistan. Health Innovation Reports. https://doi.org/10.64048/hir.v2n2.001
Vancouver
Butt NI. Methotrexate formulation and dosing errors in rheumatology practice: a perspective from Pakistan. Health Innovation Reports. 2026. doi:10.64048/hir.v2n2.001
BibTeX
@article{Butt2026,
author = {Butt, Nauman Ismat},
title = {Methotrexate formulation and dosing errors in rheumatology practice: a perspective from Pakistan},
journal = {Health Innovation Reports},
year = {2026},
doi = {10.64048/hir.v2n2.001}
}
EUVIMED